Larry Corey, M.D.

Dr. Corey is an internationally renowned expert in virology, immunology and vaccine development, and his research focuses on herpes viruses, HIV and other viral infections, particularly those associated with cancer. He has extensive experience with the development of experimental vaccines for both genital herpes and HIV, and his lab has pioneered novel tests for diagnosing and monitoring therapies for viral infections. His honors and awards include election to the American Academy of Arts and Sciences and to the National Academy of Medicine.

Click here to learn more

He is also the recipient of the American Society for STD Research Parran Award, the University of Michigan Medical School Distinguished Alumnus Award, and the Cubist Award from the American Society of Microbiology. Corey received his bachelor’s and medical degrees from the University of Michigan in Ann Arbor, Michigan, and his infectious diseases training at the University of Washington. He has authored more than 700 scientific publications, 12 books and 150 editorials and book chapters, and has served on numerous editorial boards and national committees.



Lee Huntsman, Ph.D.

After distinguished service in academic leadership spanning more than two decades, Lee Huntsman was named President Emeritus by the University of Washington Board of Regents in July 2004. In this role, he provides leadership in a variety of scientific and policy initiatives underway at the University and in the State of Washington. From 2005 to 2012, he also served as the first executive director of the Life Sciences Discovery Fund Authority, a public-private partnership intended to advance life sciences research in the state.

Click here to learn more

A particular focus during Dr. Huntsman’s tenure at the UW has been the identification and initiation of new interdisciplinary programs. Currently he is exploring ways the UW and Washington state might become more agile and successful in the reinvention of health care. Dr. Huntsman has been elected Fellow of the American Institute of Medical and Biological Engineering, the Biomedical Engineering Society and the American Association for the Advancement of Science.
David Lacey, M.D.

Throughout a distinguished career, Dr. Lacey has focused on the use of science and technology to help create new medicines that make a difference in the lives of patients. Dr. Lacey is a former Senior Vice President and Head of Discovery Research at Amgen. He has over 30 years of basic and clinical research experience. Dr. Lacey played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen as well as the development of the anti-RANKL human antibody known as denosumab.

Click here to learn more

As an experienced biopharmaceutical executive he views the challenges of discovery research in the current post-genome era as highly competitive, facing increasing regulatory complexity, but opportunity rich requiring the coordination and understanding of diverse scientific specialties and newly evolving, disruptive technologies. Dr. Lacey received both his B.A. andM.D. from the University of Colorado and his accomplishments were recognized through his nomination to Phi Beta Kappa and Alpha Omega Alpha, respectively. Dr. Lacey trained in pathology at the Washington University Medical Center, St. Louis, MO.


Tomas Mustelin, M.D., PhD.

Tomas graduated from medical school at the University of Helsinki in 1987, where he also earned his PhD degree in immunology in 1988 and continues to hold a position as Docent in cell biology since 1992. After post doc training at Scripps Clinic in La Jolla, CA, and finishing his residency in rheumatology, lung medicine and family practice, he joined the faculty of the La Jolla Institute for Allergy and Immunology in La Jolla, CA in late 1992.

Click here to learn more

In 1999 he became a Professor and in 2004 a Program Director and the Burnham Institute for Medical Research until 2007 when he left academia to pursue a career in industry. He remains an Adjunct Professor at the Sanford-Burnham Medical Research Institute and at the UCSD School of Medicine.

As Vice President leading the Inflammatory Diseases group at Amgen 2007 – 2011, and Site Head for Amgen’s operations in Seattle, Washington, Tomas led the teams that brought 14 candidate drugs to the clinic for diseases such as rheumatoid arthritis, psoriasis, lupus, Crohn’s disease, ulcerative colitis, multiple sclerosis, and B cell lymphoma. These candidate drugs included both small-molecule drugs and biologics and most of them are still active in clinical trials today, including brodalumab, which was approved by the FDA for psoriasis in February 2017. In April 2012, five of these molecules were the subject of a co-development agreement between Amgen and Astra Zeneca/MedImmune.

2012 – 2016, Tomas worked at MedImmune (AstraZeneca) leading the discovery of new biology in respiratory, Inflammatory and autoimmune diseases, the identification of new drug targets, the selection of novel therapeutics, as well as their preclinical development strategy. His group delivered 11 candidate drugs for clinical trials in asthma, atopic dermatitis, rheumatoid arthritis, lupus, Sjögren’s syndrome, and other autoantibody-mediated diseases. From July 2012 to March 2013, Tomas served as the interim Head of Research, overseeing 800 staff in RIA, Oncology, Infectious Diseases, Antibody Development and Protein Engineering, and Translational Sciences.

In July 2016, Tomas joined Gilead Sceinces as VP of Immunology and Inflammation.

Tomas has published over 220 papers in scientific journals, reporting novel findings in immunology, cell biology, cancer biology, genetics, genomics, drug discovery, nanotechnology, and many human diseases. He has reviewed manuscripts for all the major journals, chaired NIH study sections, and reviewed grant applications for NIH, NSF, and other grant agencies, and serves on several boards and councils.